{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacogenetic+Testing&page=2", "query": { "intervention": "Pharmacogenetic Testing", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacogenetic+Testing&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-23T17:12:27.997Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02453620", "title": "Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Breast Adenocarcinoma", "Invasive Breast Carcinoma", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Blood Sample", "type": "OTHER" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Entinostat", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2016-02-12", "completion_date": "2027-09-11", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-09-23T17:12:27.997Z", "location_count": 5, "location_summary": "Duarte, California • New Haven, Connecticut • Baltimore, Maryland + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02453620" }, { "nct_id": "NCT04893395", "title": "Assessment of the Impact of Clinical Pharmacogenomics on Real and Potential Medication Use in Veterans", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pharmacogenetics", "Depressive Disorder, Major", "Medication Therapy Management" ], "interventions": [ { "name": "Pharmacogenomic Screening", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Auburn University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 0, "start_date": "2021-09-01", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2022-08-09", "last_synced_at": "2026-09-23T17:12:27.997Z", "location_count": 1, "location_summary": "Tuscaloosa, Alabama", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04893395" }, { "nct_id": "NCT01495845", "title": "Implementation of a Personalized Medicine (Pharmacogenomics) Service in a Community Pharmacy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stroke", "Transient Ischemic Attack", "Myocardial Infarction" ], "interventions": [ { "name": "Pharmacogenomics testing for clopidogrel responsiveness", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2011-12", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2012-06-08", "last_synced_at": "2026-09-23T17:12:27.997Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01495845" }, { "nct_id": "NCT02428660", "title": "Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cytochrome P450 CYP2D6 Enzyme Deficiency", "Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant", "Ultrarapid Metabolizer Due to Cytochrome P450 CYP2D6 Variant", "Extensive Metabolizer Due to Cytochrome P450 CYP2D6 Variant", "Cytochrome P450 CYP2C9 Enzyme Deficiency", "Cytochrome P450 CYP2C19 Enzyme Deficiency", "Drug Metabolism, Poor, CYP2D6-RELATED", "Drug Metabolism, Poor, CYP2C19-RELATED", "CYP2D6 Polymorphism" ], "interventions": [ { "name": "Pharmacogenetic testing", "type": "GENETIC" }, { "name": "Software-based drug & gene interaction risk analysis", "type": "OTHER" }, { "name": "MTM", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "Genelex Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 341, "start_date": "2015-02", "completion_date": "2017-02", "has_results": false, "last_update_posted_date": "2017-02-23", "last_synced_at": "2026-09-23T17:12:27.997Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02428660" }, { "nct_id": "NCT03322189", "title": "Pharmacogenomics Results Affect Patients' Plan of Care and Changes in Medication Prescription(s)", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pharmacogenomic" ], "interventions": [ { "name": "pharmacogenomic", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Data Collection Analysis Business Management", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 200, "start_date": "2017-03-22", "completion_date": "2020-04-01", "has_results": false, "last_update_posted_date": "2019-01-23", "last_synced_at": "2026-09-23T17:12:27.997Z", "location_count": 1, "location_summary": "Land O' Lakes, Florida", "locations": [ { "city": "Land O' Lakes", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03322189" }, { "nct_id": "NCT01937052", "title": "Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Sample collection", "type": "OTHER" }, { "name": "Patient-reported outcomes", "type": "BEHAVIORAL" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2012-05-09", "completion_date": "2024-11-25", "has_results": false, "last_update_posted_date": "2024-12-13", "last_synced_at": "2026-09-23T17:12:27.997Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01937052" }, { "nct_id": "NCT02631746", "title": "Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Adult T-Cell Leukemia/Lymphoma", "Adult T-Cell Leukemia/Lymphoma", "Chronic Adult T-Cell Leukemia/Lymphoma", "HTLV-1 Infection", "Lymphomatous Adult T-Cell Leukemia/Lymphoma", "Smoldering Adult T-Cell Leukemia/Lymphoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pharmacogenomic Study", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-02-23", "completion_date": "2019-07-31", "has_results": true, "last_update_posted_date": "2025-03-14", "last_synced_at": "2026-09-23T17:12:27.997Z", "location_count": 6, "location_summary": "Baltimore, Maryland • Bethesda, Maryland • The Bronx, New York + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02631746" }, { "nct_id": "NCT00769288", "title": "FAU in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Grade III Lymphomatoid Granulomatosis", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Adult T-cell Leukemia/Lymphoma", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Small Lymphocytic Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "2'-F-ara-deoxyuridine", "type": "DRUG" }, { "name": "positron emission tomography", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "pharmacogenomic studies", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2009-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-07", "last_synced_at": "2026-09-23T17:12:27.997Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00769288" }, { "nct_id": "NCT00063895", "title": "Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIA Ovarian Epithelial Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IIIB Ovarian Epithelial Cancer", "Stage IIIC Ovarian Epithelial Cancer", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVC Squamous Cell Carcinoma of the Larynx", "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Oropharynx" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-09", "last_synced_at": "2026-09-23T17:12:27.997Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00063895" }, { "nct_id": "NCT03113890", "title": "McLean and Genomind Prospective Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Major Depressive Disorder", "PTSD" ], "interventions": [ { "name": "Phlebotomy - Folate", "type": "GENETIC" }, { "name": "Cheek Swab", "type": "GENETIC" }, { "name": "Self-report surveys", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "Mclean Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2017-09-22", "completion_date": "2020-07-31", "has_results": false, "last_update_posted_date": "2021-02-23", "last_synced_at": "2026-09-23T17:12:27.997Z", "location_count": 1, "location_summary": "Belmont, Massachusetts", "locations": [ { "city": "Belmont", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03113890" } ] }